ESTRO 2022 - Abstract Book

S1014

Abstract book

ESTRO 2022

Results 57 patients with a median age of 60 years old (32 – 85) were retrospectively analyzed. Fifty-three women (93%) had stage III BC, whose 24 (45%) were stage IIIC. All patients underwent axillary dissection along with breast conservative surgery in 34 (60%) cases and with radical mastectomy in 23 (40%) cases; 4 (7%) patients had surgical reconstruction. Thirty-four (60%) patients underwent HF RT to whole breast plus regional nodal irradiation (RNI) and 23 (42%) patients received HF post- mastectomy RT plus RNI. At a median follow-up of 80 months (30 – 113), the combined loco-regional recurrence rate was 7% and the 7-year LRR-free survival was 93% (95% Confidence Interval [CI], 74% - 95%). Sixteen patients (28%) developed distant metastasis, of which 8 (50%) were bone, 3 (19%) were parenchymal and 5 (31%) both. The 7-year DMFS was 76% (95% CI, 52% - 78%). Death Occurred in 12 (22%) patients. The 7-year OS was 67% (95% CI, 50% – 80%). Grade 1 and grade 2 acute skin toxicity occurred in 19 (35%) and 9 (16%) patients, respectively. No grade 2 and grade 3 late skin toxicity have been observed in all patients. Late arm lymphedema was reported in 12 (21%) women, with arm impairment in 8 (75%) cases.